Stock Analysis
- India
- /
- Medical Equipment
- /
- NSEI:NURECA
Nureca Full Year 2024 Earnings: ₹1.79 loss per share (vs ₹8.25 loss in FY 2023)
Nureca (NSE:NURECA) Full Year 2024 Results
Key Financial Results
- Revenue: ₹919.3m (down 17% from FY 2023).
- Net loss: ₹17.9m (loss narrowed by 78% from FY 2023).
- ₹1.79 loss per share (improved from ₹8.25 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Nureca shares are down 3.6% from a week ago.
Risk Analysis
We should say that we've discovered 2 warning signs for Nureca (1 shouldn't be ignored!) that you should be aware of before investing here.
Valuation is complex, but we're helping make it simple.
Find out whether Nureca is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're helping make it simple.
Find out whether Nureca is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NSEI:NURECA
Mediocre balance sheet and slightly overvalued.